Vitamin D as a Neuroimmune Signal: Mental Health Applications Beyond Bone

At a Glance

Vitamin D has been framed for decades as a bone mineral. That framing is wrong — or at minimum, radically incomplete. We now understand that vitamin D is a pleiotropic steroid hormone that acts as a neuroimmune signal throughout the entire lifespan: from fetal neural tube formation to the pace of cognitive aging in the eighth decade. In my clinical practice, optimising vitamin D is one of the first steps I take with patients who present with treatment-resistant depression, early cognitive decline, or a family history of schizophrenia. This is not fringe medicine — it is a reasonable application of a substantial and growing evidence base.

How Vitamin D Reaches the Brain

Vitamin D does not stop at the gut and the skeleton. The vitamin D receptor (VDR) is expressed throughout the central nervous system — in neurons, astrocytes, oligodendrocytes, and microglia. The enzyme that activates the precursor 25(OH)D into the biologically active calcitriol (1,25(OH)₂D) is also expressed locally in brain tissue, meaning the brain can auto-regulate its own vitamin D signalling rather than depending entirely on circulating calcitriol.

Key receptor locations include:

• Prefrontal cortex — executive function, emotional regulation
• Hippocampus — memory consolidation, depression vulnerability
• Substantia nigra and basal ganglia — dopamine synthesis pathways
• Hypothalamus — circadian rhythm and stress axis regulation
• Cerebellum — motor coordination, increasingly linked to autism phenotypes

This VDR distribution maps directly onto the psychiatric conditions where vitamin D deficiency carries the highest risk. It is not coincidental that low vitamin D correlates with depression (hippocampus and PFC), schizophrenia (dopamine circuits), and autism (cerebellar development).

The Developmental Window: Prenatal and Early Childhood

Perhaps the most compelling evidence for vitamin D as a brain signal comes from developmental research. Several large epidemiological studies and animal models converge on a consistent finding: vitamin D deficiency during critical developmental windows increases the risk of neurodevelopmental disorders.

Schizophrenia

The association between prenatal vitamin D deficiency and schizophrenia risk is one of the most replicated findings in psychiatric epidemiology. Studies from the Danish Psychiatric Biobank have shown that neonates with the lowest vitamin D levels at birth carry an approximately 44% increased risk of schizophrenia compared with those in the reference range. The mechanism is partially understood: vitamin D deficiency during fetal development disrupts dopamine D2 receptor density, reduces NGF (nerve growth factor) expression, and alters the trajectory of neuronal migration in the prefrontal cortex.

Seasonality of birth — a classic epidemiological observation where schizophrenia risk is higher for those born in late winter and spring — is partially explained by the lower maternal vitamin D status during gestation in northern latitudes.

Autism Spectrum Disorder

The vitamin D-autism link is more recent but accumulating quickly. A 2019 meta-analysis of 11 studies (>19,000 participants) found significantly lower serum 25(OH)D in children with ASD compared with controls. Proposed mechanisms include:

• Vitamin D regulation of oxytocin gene expression (critical for social bonding)
• VDR modulation of cerebellar development
• Vitamin D as a suppressor of microglial overactivation during critical developmental windows

Several small RCTs in children with ASD have shown improvement in irritability, hyperactivity, and social awareness scores following vitamin D supplementation, particularly at doses achieving serum levels above 40 ng/mL.

Depression: Vitamin D and the Serotonin Synthesis Pathway

The link between vitamin D and depression is bidirectional and mechanistically grounded. Low vitamin D causes depression-like states; depression behaviours (indoor lifestyle, poor diet) cause lower vitamin D. Clinically, it is important to treat both.

The key mechanistic pathway: vitamin D directly upregulates tryptophan hydroxylase 2 (TPH2), the rate-limiting enzyme for central serotonin synthesis. It simultaneously downregulates the serotonin transporter (SERT), increasing serotonin availability in the synaptic cleft. In parallel, vitamin D inhibits indoleamine 2,3-dioxygenase (IDO), the enzyme that shunts tryptophan toward the kynurenine pathway (a route associated with depression and neuroinflammation) rather than toward serotonin.

This means that vitamin D deficiency creates a neurochemical environment that:

1. Reduces serotonin synthesis at the source
2. Increases serotonin reuptake
3. Diverts tryptophan away from serotonin toward neuroinflammatory metabolites

A 2020 Cochrane-adjacent systematic review of 61 observational studies (>300,000 participants) found a significant inverse correlation between serum 25(OH)D and depressive symptoms. RCT evidence is more mixed, which is expected: vitamin D supplementation benefits depressed patients who are deficient, not those who are replete. This is why testing before treating matters.

Neuroinflammation: Vitamin D as a Brake on Microglial Overactivation

Neuroinflammation — chronic low-grade activation of the brain’s immune cells (microglia and astrocytes) — underlies a growing number of psychiatric and neurodegenerative conditions. Vitamin D is one of the most potent endogenous suppressors of this process.

Via VDR activation in microglia, calcitriol:

• Suppresses NF-κB signalling, reducing production of IL-6, IL-1β, and TNF-α
• Promotes the shift from the pro-inflammatory M1 microglial phenotype toward the anti-inflammatory M2 phenotype
• Upregulates production of neurotrophic factors including BDNF and NGF
• Protects the blood-brain barrier by maintaining tight junction protein expression (occludin, claudin-5)

In practical terms, a patient with chronic neuroinflammation — from Lyme disease, mold toxicity, long COVID, or autoimmune encephalitis — who is also vitamin D deficient has lost a critical biological brake on the very process causing their cognitive and psychiatric symptoms. Optimising vitamin D in these patients is not optional; it is foundational.

Cognitive Decline and Dementia

The epidemiological signal connecting vitamin D to cognitive decline is substantial. A 2014 study in Neurology (n=1,658, mean follow-up 5.6 years) found that participants with severe vitamin D deficiency (<10 ng/mL) had a 122% increased risk of Alzheimer’s disease. A 2022 meta-analysis of 15 longitudinal studies confirmed an inverse relationship between vitamin D status and dementia risk, with the risk curve steepening markedly below 25 ng/mL.

Proposed mechanisms for cognitive protection:

While RCT evidence for dementia prevention remains challenging to generate (long timescales, compliance issues), the convergence of mechanistic and observational data is sufficient to warrant optimising vitamin D in any patient with cognitive complaints.

Clinical Protocol: Targeting Psychiatric Indications

Testing

Always test before supplementing. Order:

• Serum 25(OH)D (the storage form — what you’re targeting)
• Serum calcium (to rule out hypercalcaemia)
• PTH (inverse relationship confirms sufficiency)
• Magnesium (deficiency impairs vitamin D conversion)

Target Level for Psychiatric Indications

For general health: ≥40 ng/mL.
For psychiatric and neuroimmune indications: 60–80 ng/mL (150–200 nmol/L).
Toxicity (hypercalcaemia) is rarely reported below 150 ng/mL with normal calcium handling; the toxicity threshold is pharmacological, not therapeutic.

Dose

Essential cofactors:

• Vitamin K2 (MK-7, 100–200 mcg/day): directs calcium to bone, not soft tissue
• Magnesium glycinate or malate (300–400 mg/day): required cofactor for 25(OH)D conversion to calcitriol
• Take with the largest fat-containing meal of the day — vitamin D is fat-soluble

Retest

Retest serum 25(OH)D at 8–12 weeks to titrate. Once at target, annual or biannual monitoring is sufficient for most patients.

Special Populations

Patients with neuroinflammatory conditions (Lyme, mold, long COVID): Target the upper end of the therapeutic range (70–80 ng/mL). Neuroinflammation increases vitamin D catabolism via CYP24A1 enzyme upregulation, meaning these patients often need higher doses to maintain a given serum level.

Patients on antiepileptics or rifampicin: These drugs induce CYP450 enzymes that accelerate vitamin D catabolism. Doses 30–50% higher than standard are often needed.

Dark skin, high latitude, or indoor lifestyle: Baseline synthesis is markedly reduced. These patients are frequently found at 10–15 ng/mL regardless of diet, and require supplementation at the higher end of the dosing table above.

Pregnancy: Maternal 25(OH)D below 30 ng/mL is associated with increased risk of gestational diabetes, preeclampsia, and — as discussed — neurodevelopmental conditions in the offspring. A safe and well-tolerated dose in pregnancy is 4,000 IU/day, well within the evidence-based range.

Related Articles

• Vitamin D: The Most Important Supplement Most People Get Wrong — foundational guide to dosing, cofactors, and immune function
• LL-37 and Vitamin D: The Immune Connection — how vitamin D drives cathelicidin antimicrobial defense
• Neuroinflammation and Brain Fog — the inflammatory basis of cognitive symptoms
• Magnesium and Sleep — a key cofactor for vitamin D that also independently supports psychiatric health
• Functional Medicine Lab Testing — how to test vitamin D and the markers that contextualise it

References

1. Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol. 2013;34(1):47-64. PMID: 22796576

2. Patrick RP, Ames BN. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar, schizophrenia, and impulsive behavior. FASEB J. 2015;29(6):2207-22. PMID: 25713056

3. Spedding S. Vitamin D and depression: a systematic review and meta-analysis comparing studies with and without biological flaws. Nutrients. 2014;6(4):1501-18. PMID: 24732019

4. Cannell JJ, Hollis BW, Zasloff M, Heaney RP. Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother. 2008;9(1):107-18. PMID: 18076342

5. Littlejohns TJ et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83(10):920-928. PMID: 25098535

6. Humble MB. Vitamin D, light and mental health. J Photochem Photobiol B. 2010;101(2):142-9. PMID: 20705468

7. Fernandes de Abreu DA et al. Vitamin D, a neuroimmune modulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology. 2009;34 Suppl 1:S265-77. PMID: 19545951

8. Mostafa GA, Al-Ayadhi LY. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. J Neuroinflammation. 2012;9:201. PMID: 22935105